Ardelyx, Inc.(ARDX) Stock Research - Grey Stern Research
Loading...

Ardelyx, Inc. (ARDX) Stock Analysis

$5.94 (1.11%)

ARDX Financial Performance


Use the table below to view Ardelyx, Inc.'s financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q2 - 2024

Metric Value Ranking among Peers
Price $5.87 -
52 Week Low $3.16 -
52 Week High $10.13 -
Market Cap $1.4 Billion 2/12
Gross Margin 86% 2/12
Profit Margin -22% 8/12
EBITDA margin -18% 1/12
Q2 - 2024 Revenue $73.2 Million 1/12
Q2 - 2024 Earnings -$16.5 Million 5/12
Q2 - 2024 Free Cash Flow -$19.5 Million 7/12
Trailing 4 Quarters Revenue $210.0 Million 1/12
Trailing 4 Quarters Earnings -$65.1 Million 5/12
Quarterly Earnings Growth 4% 5/12
Annual Earnings Growth 33% 4/12
Quarterly Revenue Growth 228% 3/12
Annual Revenue Growth 272% 3/12
Cash On Hand $41.9 Million 8/12
Short Term Debt $3.6 Million 6/12
Long Term Debt $100.2 Million 3/12

Ardelyx, Inc. Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Ardelyx, Inc.'s metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE -1.00 2/12
PS 6.58 5/12
PB 9.40 1/12
PC 32.99 1/12
Liabilities to Equity 1.34 3/12
ROA -0.19 3/12
ROE -0.44 5/12
Current Ratio 1.75 8/12
Quick Ratio 0.95 8/12
Long Term Debt to Equity 0.68 3/12
Debt to Equity 0.71 3/12
Burn Rate 1.96 7/12
Cash to Cap 0.03 12/12
CCR 1.19 4/12
EV to EBITDA -110.63 12/12
EV to Revenue 6.88 5/12

Company Details

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

CEO: Mr. Michael Raab

Website: https://www.ardelyx.com

Address: 34175 Ardenwood Blvd Fremont, CALIFORNIA

Exchange: NASDAQ Global Market

Industry: Biotechnology

Ardelyx, Inc. Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Ardelyx, Inc.. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Lexicon Pharmaceuticals, Inc. LXRX $589.2 Million
BioLineRx Ltd. BLRX $43.6 Million
Verastem, Inc. VSTM $120.7 Million
Seres Therapeutics, Inc. MCRB $126.4 Million
AVROBIO, Inc. AVRO $5.2 Million
Hepion Pharmaceuticals, Inc. HEPA $3.6 Million
HOOKIPA Pharma Inc. HOOK $128.5 Million
PDS Biotechnology Corporation PDSB $125.2 Million
Inozyme Pharma, Inc. INZY $320.6 Million
ImmunityBio, Inc. IBRX $2.3 Billion
Terns Pharmaceuticals, Inc. TERN $665.4 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ARDX Income Statements
Quarter Year Revenue Earnings
Q2 2024 $ 73.2 Million -$16.5 Million
Q1 2024 $ 46.0 Million -$26.5 Million
Q4 2023 $ 34.4 Million -$28.8 Million
Q3 2023 $ 56.4 Million $6.6 Million
Q2 2023 $ 22.3 Million -$17.1 Million
Q1 2023 $ 11.4 Million -$26.8 Million
Q4 2022 $ 44.2 Million $10.7 Million
Q3 2022 $ 5.0 Million -$22.9 Million

View All

ARDX Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q2 2024 $41.9 Million $343.5 Million $104.9 Million $147.0 Million
Q1 2024 $36.1 Million $342.4 Million $104.9 Million $150.9 Million
Q4 2023 $21.5 Million $297.6 Million $56.0 Million $166.8 Million
Q3 2023 $33.8 Million $289.4 Million $34.4 Million $191.2 Million
Q2 2023 $30.1 Million $211.2 Million $34.9 Million $123.2 Million
Q1 2023 $92.5 Million $217.0 Million $35.7 Million $125.4 Million
Q4 2022 $96.1 Million $190.1 Million $36.5 Million $98.3 Million
Q3 2022 $61.6 Million $144.7 Million $37.2 Million $66.9 Million

View All

ARDX Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q2 2024 -$19.5 Million -$131,000 $5.7 Million
Q1 2024 -$35.9 Million -$150,000 $14.7 Million
Q4 2023 -$8.8 Million -$43,000 -$12.3 Million
Q3 2023 -$21.7 Million -$194,000 $3.7 Million
Q2 2023 $0 $0 $86.1 Million
Q1 2023 -$44.8 Million -$14,000 -$3.7 Million
Q4 2022 $14.2 Million -$55,000 $34.5 Million
Q3 2022 -$25.4 Million $0 $8.2 Million

View All